Floatz logo

(+)-VINCRISTINE

Ependymoma Recurrent

Medical University of ViennaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Ependymoma Recurrent cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Medical University of Vienna
Phase 2CCC
Dfn-15
Medical University of Vienna
Phase 2CCC
Thalidomide
Medical University of Vienna
Phase 2CCC
Irinotecan
Medical University of Vienna
Phase 2CCC
ETOPOSIDE
Medical University of Vienna
Phase 2CCC
Fenofibric Acid
Medical University of Vienna
Phase 2CCC

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →